NanoViricides, Inc. (NYSE American: NNVC) announced that the Democratic Republic of Congo’s regulatory agency, ACOREP, has approved the start of a Phase II clinical trial evaluating NV-387 for the treatment of MPox caused by hMPXV infection. The trial will assess safety and effectiveness, pending final document submissions.
“This is an important milestone in regulatory development of NV-387,” said Anil R. Diwan, PhD, President and Executive Chairman. NV-387 is designed to mimic human cells to trap and destroy viruses and has shown potential as a broad-spectrum antiviral targeting up to 95% of human pathogenic viruses. The Company believes the drug could represent a major breakthrough in antiviral therapy, similar to how antibiotics transformed bacterial disease treatment.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral drug being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company also has other advanced drug candidates, including NV-HHV-1 for the treatment of Shingles.
The approval in the DRC marks a critical step for NanoViricides as it advances NV-387 into human trials. The company’s platform technology is based on the TheraCour nanomedicine technology, which it licenses from AllExcel. NanoViricides holds exclusive perpetual licenses for several drugs targeting a range of human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, Ebola, and certain Coronaviruses.
For more information, see the full press release at https://ibn.fm/WdFf1. The latest news and updates relating to NNVC are available at https://ibn.fm/NNVC.
